Bazanov, D.R.; Pervushin, N.V.; Savin, E.V.; Tsymliakov, M.D.; Maksutova, A.I.; Savitskaya, V.Y.; Sosonyuk, S.E.; Gracheva, Y.A.; Seliverstov, M.Y.; Lozinskaya, N.A.;
et al. Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core. Pharmaceuticals 2022, 15, 444.
https://doi.org/10.3390/ph15040444
AMA Style
Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Savitskaya VY, Sosonyuk SE, Gracheva YA, Seliverstov MY, Lozinskaya NA,
et al. Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core. Pharmaceuticals. 2022; 15(4):444.
https://doi.org/10.3390/ph15040444
Chicago/Turabian Style
Bazanov, Daniil R., Nikolay V. Pervushin, Egor V. Savin, Michael D. Tsymliakov, Anita I. Maksutova, Victoria Yu. Savitskaya, Sergey E. Sosonyuk, Yulia A. Gracheva, Michael Yu. Seliverstov, Natalia A. Lozinskaya,
and et al. 2022. "Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core" Pharmaceuticals 15, no. 4: 444.
https://doi.org/10.3390/ph15040444
APA Style
Bazanov, D. R., Pervushin, N. V., Savin, E. V., Tsymliakov, M. D., Maksutova, A. I., Savitskaya, V. Y., Sosonyuk, S. E., Gracheva, Y. A., Seliverstov, M. Y., Lozinskaya, N. A., & Kopeina, G. S.
(2022). Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core. Pharmaceuticals, 15(4), 444.
https://doi.org/10.3390/ph15040444